VALENCIA, Calif., Jan. 12 /PRNewswire-FirstCall/ -- MannKind Corporation , focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at three upcoming healthcare conferences:
* VisionGain 3rd Annual Strategic Forum-Advancing Treatments for Diabetes and Metabolic Syndrome on January 18, 2007 at 2:00 pm (GMT) to be held at BSG House, 226-236 City Road, London * Wachovia Securities 2007 Small and Mid Cap Healthcare Conference on January 30, 2007 at 1:30 pm (EST) at The Langham Hotel, 250 Franklin Street, Boston, Massachusetts * Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 7, 2007 at 9:20 am (EST) at The Grand Hyatt Hotel, New York, New York
Interested parties can access a link to the live webcasts of the latter two presentations in the Investor Relations section of the Company’s website at www.mannkindcorp.com. A replay of each presentation will be available for 14 days.
About MannKind Corporation
MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit www.mannkindcorp.com.
MannKind Corporation
CONTACT: Dick Anderson, Chief Financial Officer of MannKind Corporation,+1-661-775-5302, danderson@mannkindcorp.com; or Investor Relations, JulieHuang (Investors), or Robert Stanislaro (Media), +1-212-850-5600,mnkd@fd.com, both for MannKind Corporation
Web site: http://www.mannkindcorp.com/
